Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332
Zhejiang Xianju Pharmaceutical Co Ltd's latest stock split occurred on May 18, 2017
The company executed a 15-for-10 stock split, meaning that for every 10 shares held, investors received 15 new shares.
Before the split, Zhejiang Xianju Pharmaceutical Co Ltd traded at 12.5801 per share. Afterward, the share price was about 7.6766.
The adjusted shares began trading on May 18, 2017. This was Zhejiang Xianju Pharmaceutical Co Ltd's 2nd stock split, following the previous one in May 8, 2014.
CMB
RNT
XELB
Zhejiang Xianju Pharmaceutical Co Ltd
Glance View
In the heart of eastern China, Zhejiang Xianju Pharmaceutical Co., Ltd. stands as a testament to China's evolving pharmaceutical prowess. Founded in 1972, Xianju Pharmaceutical has carved out a niche in the global healthcare market by specializing in the production of corticosteroids and hormone APIs (Active Pharmaceutical Ingredients). What sets Xianju apart is its relentless focus on research and development, enabling the company to produce a wide array of steroid and hormone products that cater to both domestic and international markets. The innovation pipeline is fueled by a robust R&D team that ensures the company remains at the forefront of pharmaceutical advancements, allowing it to consistently meet the stringent quality standards expected in this highly regulated industry. The company's financial engine runs on its ability to manufacture these high-demand products efficiently and at scale, leveraging advanced technologies and integrated production processes. This operational efficiency provides Xianju a competitive edge in price stability and market reach. The revenue stream is diversified yet strategically concentrated on its core competencies, allowing Xianju to capitalize on rising global demands for hormone therapies and steroid-related medical treatments. By maintaining strong relationships with global partners and continuously expanding its distribution networks, Zhejiang Xianju Pharmaceutical not only sustains its profitability but also plays a critical role in shaping healthcare outcomes around the world. The company's growth trajectory suggests a finely balanced strategy that combines innovation, production excellence, and market expansion.
You don't have any saved screeners yet